Mojia Biotech, a Shanghai, China-based bio-manufacturing company, raised $80M in Series B funding.
The round was led by Temasek with participation from LYZZ Capital, Sento Investment, Bits x Bites, Asia Green Fund.
The company intends to use the funds to commercialize its Viridimin™ brand of animal-feed additives, scale up manufacturing capacity for Aliphane™ series of bio-based materials, advance its product pipeline and expand its global R&D capabilities.
Led by Ansen Chiew, Mojia Biotech is a product-focused bio-manufacturing company dedicated to the production of food ingredients and chemical materials using renewable carbon sources and green processes. In the past few years, the company has developed innovative pathways to produce Viridimin™ brand of Vitamin B5. The second product that Mojia Biotech aims to bring to the market is Aliphane™ series of biopolymer products, which is extremely versatile and has great potential in coating and adhesive applications.